FIRE-6
Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer. The phase II FIRE-6-Avelumab study
II
Status: Rekrutierung beendet
Zeitraum
2019
2020
Zentren
15
15
Keine Zentren gesucht
Patienten
55
57
14.04.2022
Identifier
AIO-KRK-0118
Kontakt
Leitung
Prof. Dr. med. Sebastian Stintzing
Ansprechpartner*in
Prof. Dr. med. Sebastian Stintzing
E-Mail sebastian.stintzing@charite.de